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ABSTRACT

ARTICLE HISTORY

Daptomycin is a bactericidal antibiotic approved for treatment of gram-positive skin and soft
tissue infections. We present a case of an 89-year-old man who presented with fever, shortness of breath and nonproductive cough on week 4 of starting daptomycin for infective
endocarditis. Computerized tomography scan showed bilateral interstitial infiltrates predominantly affecting the lower lobes. He also had peripheral eosinophilia of 6%. He was diagnosed
with eosinophilic pneumonia secondary to daptomycin use. His symptoms improved with
discontinuation of daptomycin and initiation of corticosteroids. Clinical correlation of pneumonia-like presentation with recent use of daptomycin should make physicians rule out this
rare adverse effect for early institution of correct treatment.
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1. Introduction
Daptomycin is a lipopeptide antibiotic approved by
the Food and Drug Administration (FDA) for treatment of skin and soft tissue infections by
Staphylococcus aureus (methicillin-susceptible or
resistant strains), Streptococcus species and vancomycin-susceptible Enterococcus faecalis [1,2] Use of daptomycin has been increasing recently as an effective
treatment
alternative
to
vancomycin
[3].
Subsequently, rare adverse effects like eosinophilic
pneumonia are being reported more frequently.
Daptomycin associated eosinophilic pneumonia
(DAEP), although rare, can mimic other pneumonia
resulting in delayed diagnosis and management, and
hence has the potential to cause serious morbidity
and mortality [1].

2. Case description
An 89-year-old man presented to the emergency
department (ED) with a history of fever, nonproductive
cough and exertional shortness of breath for a few days.
He was started 4 weeks previously on intravenous daptomycin for 6 weeks for coagulase-negative staphylococcal bacteremia and infective endocarditis of mitral
valve following a urinary procedure. Daptomycin was
chosen in this patient for once daily dosing. He was a
nonsmoker with no history of chronic obstructive pulmonary disease or asthma. In the ED, he was afebrile
(temperature 99.8°F) with a heart rate of 77 bpm, blood
pressure of 129/74 mm Hg and respiratory rate of 29
breaths per minute. His initial oxygen saturation was
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72% on room air and required high flow oxygen to
maintain his oxygen saturation. Chest examination
revealed vesicular breath sounds with diffuse rales.
Cardiac auscultation was normal. The rest of the physical examination was unremarkable.
Pertinent labs included white count of 7900/µl
with peripheral eosinophilia of 6% (reference range:
0.0–6.0%), Eosinophil count 500/µl (reference range:
150–300/uL), C-reactive protein 27.95 mg/dL (reference range: <1.00 mg/dL), erythrocyte sedimentation
rate 54 mm/h (reference range: 0–15 mm/h) and
brain natriuretic peptide 102 pg/mL (reference
range: 0–100 pg/mL). Electrocardiogram was unremarkable. Chest X-ray demonstrated hazy bilateral
airspace opacification predominantly in the lower
lobes. Computerized tomography (CT) scan of the
chest revealed bilateral lower lobe ground-glass opacification with interlobular septal thickening
(Figure 1). Streptococcus pneumoniae and Legionella
urinary antigens were negative. ANA, Rheumatoid
factor, ANCA and respiratory pathogen panel were
negative. Patient lives in Pennsylvania and denied
travel outside the USA. Stool ova and parasites done
were negative. Urine drug screen was not done but
patient denied substance abuse. He was not on any
over the counter pain medications. Blood and urine
cultures done during hospital stay were negative.
With concern for DAEP, daptomycin was discontinued. Intravenous methylprednisolone at 60 mg
every 6 h was started. Daptomycin was switched to
intravenous vancomycin to complete the 6-week antibiotic course for infective endocarditis. He was also
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Figure 1. CT scan of chest showing bilateral diffuse ground glass opacity of lung parenchyma on presentation.

started on intravenous cefepime and metronidazole
(2-week course) for broad-spectrum coverage of
pneumonia. Resolution of eosinophilia (0.8%) with
the appearance of neutrophilic leucocytosis (92.3%
neutrophils with WBC of 12,500/µl) were noted.
With improvement of his respiratory status,
his methylprednisolone was stopped, and he was
started on prednisone taper for 6 weeks. He was
also started on prophylactic sulfamethoxazole-trimethoprim 800/160 mg two times daily until his
prednisone would drop down to 20 mg daily. High
flow oxygen was weaned off to nasal cannula oxygen.
Repeat CT chest (Figure 2) 2 weeks later revealed
partial clearing of the diffuse ground-glass opacities. His

respiratory status had improved, and he was maintaining
saturation in low 90s on 2–3-L oxygen via nasal cannula.
He was discharged home on prednisone taper, prophylactic sulfamethoxazole-trimethoprim, and supplemental
oxygen. Unfortunately, he was lost to follow-up.

3. Discussion
DAEP was first reported in 2007. DAEP is characterized by eosinophilic infiltration of the lung parenchyma ranging from asymptomatic infiltrates to
acute respiratory distress syndrome necessitating
mechanical ventilation [4]. It is believed that parenchymal damage secondary to destruction of

Figure 2. CT scan of chest showing improved opacity of lung parenchyma 2 weeks after discontinuation of daptomycin.
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pulmonary surfactant and induction of allergic reaction by daptomycin causes DAEP [4–7].
DAEP is characteristically seen in elderly males and
usually manifests as a febrile illness lasting a few weeks
and is accompanied by constitutional symptoms, dyspnea and nonproductive cough [4,8]. Kim et al developed a case definition for DAEP and classified it as
definite, probable, possible and unlikely based on fulfillment of criteria. Diagnosis is ‘definite’ if there is a
history of exposure to daptomycin, fever, dyspnea
requiring oxygen or mechanical ventilation, pulmonary infiltrates identified on chest X-ray or CT scan,
bronchoalveolar lavage (BAL) with >25% eosinophils
and clinical improvement with discontinuation of daptomycin. Diagnosis is ‘probable’ if there is a history of
daptomycin exposure, dyspnea requiring oxygen or
mechanical ventilation, pulmonary infiltrates identified
on chest X-ray or CT scan, peripheral eosinophilia and
clinical improvement following daptomycin withdrawal [4], as in our case. We did not do a bronchoscopy
as our patient was frail. Initial diagnostic studies may
show hypoxemia, infiltrates on chest imaging and variably, peripheral eosinophilia [4]. Pulmonary eosinophilic infiltrates or BAL eosinophilia is a cornerstone
for diagnosis [2,9]. Discontinuation of daptomycin
with or without corticosteroid is the mainstay of management [4,8]. Corticosteroid is believed to rapidly
reverse the inflammation and thereby improve the
hypoxia [8]. Patients are usually started on intravenous
methylprednisone 60–125 mg every 6–8 h, transitioned
to oral prednisone 40–60 mg daily with clinical
improvement and is tapered over 2–6 weeks to avoid
relapse [8,10].

4. Differential diagnosis
Conditions that can have a similar presentation of
dyspnea and bilateral ground glass pulmonary infiltrates include pneumonia, hypersensitivity pneumonitis, alveolar proteinosis and cryptogenic organizing
pneumonia. The patient did not have constitutional
symptoms, sputum production with negative pneumococcal and Legionella urinary antigens making
pneumonia unlikely. Pneumocystis jirovecii pneumonia without constitutional symptoms, history of exposure to HIV or high-risk behavior can be ruled out.
Alveolar proteinosis is a rare diagnosis which is
uncommon with no history of smoking. Lastly, cryptogenic organizing pneumonia is characteristically
associated with a change in location of consolidation
which was absent in our patient on serial imaging.

5. Conclusion
DAEP is an uncommonly observed adverse effect of
daptomycin. Its incidence will increase with increasing use of daptomycin. Clinicians must be aware of

this adverse effect and presentation for early discontinuation of the medication and institution of
corticosteroids.

Key points
(1) Eosinophilic pneumonia is a rare side effect of
daptomycin.
(2) It presents as febrile illness, nonproductive
cough and shortness of breath within a few
weeks of initiation of daptomycin.
(3) Diagnosis is ‘definite’ if there is a history of
exposure to daptomycin, fever, dyspnea
requiring oxygen or mechanical ventilation,
pulmonary infiltrates identified on chest
X-ray or CT scan, bronchoalveolar lavage
(BAL) with >25% eosinophils and clinical
improvement
with
discontinuation
of
daptomycin.
(4) Discontinuation of daptomycin and corticosteroids are the primary treatment measures.
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